Celgene Pays $340 Million For Gloucester And Its New Drug
This article was originally published in The Pink Sheet Daily
Executive Summary
Celgene already sells several hematological cancer meds, so the deal shouldn't require new marketing infrastructure.
You may also be interested in...
For Its Latest Epigenetics Deal, Celgene Takes Option To Buy Acetylon
A $100 million, non-dilutive investment will keep Acetylon off the market, giving Celgene the right to buy it for a minimum of $500 million up-front within a pre-determined time window. For now, Acetylon retains all rights to its pipeline, including Phase Ib multiple myeloma drug ACY-1215.
Former Yaupon Therapeutics Raises $15 Million In Debt To Prepare To Commercialize Its First Product
Now called Ceptaris, the company is awaiting FDA approval of mechlorethamine gel, a topical formulation of a cytotoxin, for early-stage CTCL.
HDAC Inhibitor Mysteries Remain As Candidates Advance
With more than a dozen candidates in the clinic and a range of indications expanding outside oncology, the histone deacetylase inhibitor class could be poised to make major inroads. But much remains to be learned about the activity, and companies are scrambling to find biomarkers.